#	Pagina
attuale pagina	/open-h2020/projects/194765/index.html

Opendata, web and dolomites

KIT

Kidney Injury Technology

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

KIT project word cloud

Explore the words cloud of the KIT project. It provides you a very rough idea of what is the project "KIT" about.

annual grows bio upfront people critical sought poses prognosis disease reference incidence penetration 2023 price health global population biomarker envisioned gold prototype market 650 transfer standard instrument aki ivd sme started worldwide patient 69 commercialization incident thereafter economic international maturity dismally company inren sales 2018 channels license marker 10 smes 7 rate acute diagnostics kit diagnostic manufacturing tests deadly unitary companies elisa revolutionary consolidation renal clinical regulated clinically expenditure thorough 35 initially billion samples 5 technological yield validation royalties competitors patented sale 2017 laid 128 transferability 1 huge income reduce human elevated vitro capacity yearly m handling acquire gt posing

Project "KIT" data sheet

The following table provides information about the project.

Coordinator	BIO-INREN SL Organization address address: NORBERTO CUESTA DUTARI 39 4 D city: SALAMANCA postcode: 37007 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Project website	http://www.bio-inren.es
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2014
Duration (year-month-day)	from 2014-11-01 to 2015-04-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	BIO-INREN SL BIO-INREN SL Organization address address: NORBERTO CUESTA DUTARI 39 4 D city: SALAMANCA postcode: 37007 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (SALAMANCA)	coordinator	50˙000.00

Map

Project objective

Bio-inRen has developed and patented a revolutionary biomarker-based diagnostic system for a highly and increasingly incident (>10% yearly) and dismally deadly disease (Acute Renal Failure -AKI) posing a huge global health and economic problem worldwide. Bio-inRen’s diagnostic system is envisioned to 1) change the concept and approach to AKI clinical handling, 2) become a reference diagnostic, 3) reduce AKI incidence (by 2.5-5% initially) and improve patient prognosis, and 4) reduce the elevated cost associated to AKI (1% of their global health expenditure, which will be reduced initially in 650 M € in this 1.35 billion people population). An ELISA-based, clinically useful prototype kit has been developed for measurement of human samples. Clinical validation has started, although Bio-inRen’s system needs thorough clinical validation to acquire technological maturity and transferability, for which Phase I and II SME instrument are necessary, on which all the company’s resources will be laid. As a new concept, Bio-inRen’s technology has no competitors in the market or under development. The In Vitro Diagnostic Market grows at a 7% annual rate and will reach $69.1 billion by 2017. AKI-specific market is estimated at 3.5 M cases and 70 M diagnostic tests of the existing gold standard marker. Because Diagnostics is a global and regulated market, Bio-inRen will license the system to large companies and SMEs in the IVD market with manufacturing capacity and international commercialization channels. Technology transfer is expected by 2018 to yield 1 M € upfront and 5% royalties on sales thereafter. 5% market penetration is sought by 2023. As of today, 5% of 70 M tests poses 3.5 M tests as Bio-inRen’s market (6.4 M tests by 2023 at 7% annual growth rate). At a unitary sale price of 20 €/test, this means 128 M €. 5% royalties will produce a yearly income of 6.4 M € to Bio-inRen, which are critical for the consolidation and growth of the company.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "KIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "KIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination